Zoetis Inc. (ZTS)
ZTS Wins European Commission Approval for New Poultry Disease Vaccine
Zoetis wins EU approval for a single-dose poultry vaccine against Newcastle and Marek's diseases, expanding its vaccine portfolio and flock protection options.
Zoetis: The 60% Decline Was Justified, But Shares Are Finally Buyable
Zoetis has seen its valuation compress dramatically, now trading at just 12x trailing earnings after a 52% 12-month share price decline. Despite decelerating growth—Q1 2026 saw just 3% revenue growth—international and livestock segments are offsetting U.S. pet care weakness. Dividend growth remains robust, with a 12-year streak and a current yield of 2.8% backed by a solid payout ratio.
Zoetis (ZTS) Suffers a Larger Drop Than the General Market: Key Insights
In the latest trading session, Zoetis (ZTS) closed at $76.09, marking a -2.22% move from the previous day.
Zoetis (ZTS) Surpasses Market Returns: Some Facts Worth Knowing
Zoetis (ZTS) concluded the recent trading session at $78.71, signifying a +1.88% move from its prior day's close.
Zoetis (ZTS) Stock Dips While Market Gains: Key Facts
Zoetis (ZTS) closed the most recent trading day at $79.57, moving 2.25% from the previous trading session.
Zoetis Inc. (ZTS) Presents at 46th Annual William Blair Growth Stock Conference Transcript
Zoetis Inc. (ZTS) Presents at 46th Annual William Blair Growth Stock Conference Transcript
Zoetis Inc. (ZTS) Presents at Stifel Jaws & Paws Conference 2026 Transcript
Zoetis Inc. (ZTS) Presents at Stifel Jaws & Paws Conference 2026 Transcript
11 'Safer' Dividend Dogs Lead 20 May Barron's 2026 Oil And Blue Chips
Barron's Oil & Blue Chip Tips for May 2026 highlight 20 stocks, with 11 deemed 'safer' based on free cash flow yields exceeding dividend yields. Top ten by yield are projected to deliver average net gains of 36.08% by May 2027, with risk/volatility 24% below the market average. Zoetis (ZTS), Danaher (DHR), and Accenture (ACN) lead in projected returns, with ZTS estimated to net 60.33% and lower-than-market volatility.
Zoetis Q1 Review: Is A Darkened Outlook Cyclical Or Structural? (Rating Downgrade)
Zoetis faces intensified US companion animal sales declines, notably from generic competition impacting key legacy drugs, Convenia and Cerenia. Despite a 30% stock drop and valuation at 12x 2026 EPS, structural headwinds from patent expirations outweigh cyclical pressures in the near term. Q1 results showed a dramatic 11% YoY decline in US companion animal sales, partially offset by international and livestock segment growth.
Zoetis Inc. (ZTS) Q1 2026 Earnings Call Transcript
Zoetis Inc. (ZTS) Q1 2026 Earnings Call Transcript
Zoetis Q1 Earnings Lag Estimates, 2026 View Cut, Stock Down
ZTS misses on Q1 earnings and cuts its 2026 revenue outlook as weaker U.S. companion animal sales pressured results, sending shares down in pre-market trading.
Zoetis Is Today's Worst S&P 500 Stock. Here's Why.
The animal-health company missed first-quarter earnings estimates.
